These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38283118)

  • 1. PEGylated porcine-human recombinant uricase: A novel fusion protein with improved efficacy and safety for the treatment of hyperuricemia and renal complications.
    Wang X; Lu H; Rong J; Sun Z; Zheng Y; Fan B; Jia Z
    Open Life Sci; 2024; 19(1):20220799. PubMed ID: 38283118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble expression of bioactive recombinant porcine-human chimeric uricase mutant employing MBP-SUMO fusion system.
    Zhou Z; Zhao H; Zhang L; Xie Q; Liu Q; Tong M; Yu X; Xiong S
    Protein Expr Purif; 2022 Jan; 189():105978. PubMed ID: 34562586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase.
    Zhang C; Fan K; Ma X; Wei D
    PLoS One; 2012; 7(6):e39659. PubMed ID: 22745806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
    Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M
    PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
    Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
    Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
    Xiong H; Zhou Y; Zhou Q; He D; Deng X; Sun Q; Zhang J
    Nanomedicine; 2016 Aug; 12(6):1557-66. PubMed ID: 27013130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia.
    Cai L; Li Q; Deng Y; Liu X; Du W; Jiang X
    Int J Mol Med; 2020 May; 45(5):1488-1500. PubMed ID: 32323736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
    Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
    J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.
    Tan QY; Zhang JQ; Wang N; Yang H; Li X; Xiong HR; Wu JY; Zhao CJ; Wang H; Yin HF
    Int J Nanomedicine; 2012; 7():3929-38. PubMed ID: 22915844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
    Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
    PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered
    Zhao R; Li Z; Sun Y; Ge W; Wang M; Liu H; Xun L; Xia Y
    Gut Microbes; 2022; 14(1):2070391. PubMed ID: 35491895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
    Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
    Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice.
    Pierzynowska K; Deshpande A; Mosiichuk N; Terkeltaub R; Szczurek P; Salido E; Pierzynowski S; Grujic D
    Front Med (Lausanne); 2020; 7():569215. PubMed ID: 33330529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme.
    Alishah K; Asad S; Khajeh K; Akbari N
    Enzyme Microb Technol; 2016 Nov; 93-94():92-98. PubMed ID: 27702489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia.
    Hao Y; Li H; Cao Y; Chen Y; Lei M; Zhang T; Xiao Y; Chu B; Qian Z
    J Biomed Nanotechnol; 2019 May; 15(5):951-965. PubMed ID: 30890227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.